Marker Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Marker Therapeutics

10/11/2022 23:08

* Marker Therapeutics Inc  MRKR.OQ  reported a quarterly
adjusted
loss of 8 cents​​ per share for the quarter ended in September.
The mean expectation of three analysts for the quarter was for a
loss of 12 cents per share.
    * Revenue was $3.95 million​; analysts expected $266.67
thousand. 
    * Marker Therapeutics Inc's reported EPS for the quarter was
a
loss of 8 cents​.
    * The mean earnings estimate of analysts had risen by
about 2% in
the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Marker Therapeutics Inc shares had risen by 3.1% this
quarter and lost 60.0% so far this year.
    * The company reported a quarterly loss of $6.92 million.
    * Wall Street's median 12-month price target for Marker
Therapeutics Inc is $1.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
10 at 11:08 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.12          -0.08          Beat
 Jun. 30 2022      -0.13          -0.11          Beat
 Mar. 31 2022      -0.13          -0.12          Beat
 Dec. 31 2021      -0.13          -0.12          Beat